Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company`s lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Website: edgewisetx.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -25.6% (LTM)

Entry Point: Share price is 169.3% higher than minimum and 59.4% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders bought company shares on $18.4 mln (1.895% of cap.)

Key Financials (Download financials)

Ticker: EWTX
Share price, USD:  (-3.6%)14.84
year average price 23.77  


year start price 16.17 2024-04-27

max close price 36.51 2024-11-06

min close price 11.42 2025-04-11

current price 14.84 2025-04-26
Common stocks: 49 575 701

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 736
Net Debt ($m): -32
EV (Enterprise Value): 704
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-04-02seekingalpha.com

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

2025-03-10seekingalpha.com

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

2024-12-31seekingalpha.com

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

2024-12-17zacks.com

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

2024-12-16businesswire.com

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

2024-12-05businesswire.com

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

2024-09-25marketbeat.com

Analyst Think There's Still Time to Get in on Edgewise, Up 332%

2024-09-19marketbeat.com

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

2024-09-19zacks.com

EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies

2024-09-19fool.com

Why Edgewise Therapeutics Stock Is Up 50% on Thursday
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EWTX EWTX EWTX EWTX EWTX EWTX EWTX EWTX EWTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-05-09 2024-02-22 2023-11-09 2023-08-10 2023-05-11 2023-02-23 2022-11-03
acceptedDate 2024-11-07 08:07:49 2024-08-08 08:06:22 2024-05-09 08:06:03 2024-02-22 08:07:05 2023-11-09 08:05:32 2023-08-10 08:01:45 2023-05-11 08:01:07 2023-02-23 16:01:20 2022-11-03 08:00:53
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 2M 0 0 0 0 0
costOfRevenue 0 534 000 525 000 533 000 448 000 0 0 0 0
grossProfit 0 -534 000 -525 000 2M -448 000 0 0 0 0
grossProfitRatio 0 0 0 0.763 0 0 0 0 0
researchAndDevelopmentExpenses 32M 30M 27M 28M 24M 20M 20M 17M 14M
generalAndAdministrativeExpenses 8M 7M 7M 6M 6M 6M 6M 5M 4M
sellingAndMarketingExpenses 0 -54 000 -52 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 8M 7M 7M 6M 6M 6M 6M 5M 4M
otherExpenses 0 0 0 0 0 0 0 0 0
operatingExpenses 40M 38M 34M 34M 29M 25M 26M 22M 18M
costAndExpenses 40M 38M 35M 34M 29M 25M 26M 22M 18M
interestIncome 6M 7M 6M 4M 4M 4M 3M 3M 764 000
interestExpense 0 0 0 3M 0 0 -3M 3M 764 000
depreciationAndAmortization 602 000 534 000 525 000 533 000 497 000 461 000 241 000 92 000 165 000
ebitda -40M -38M -34M -33M -29M -25M -26M -22M -18M
ebitdaratio 0 0 0 -14.8 0 0 0 0 0
operatingIncome -40M -38M -35M -34M -29M -25M -26M -22M -18M
operatingIncomeRatio 0 0 0 -15.036 0 0 0 0 0
totalOtherIncomeExpensesNet 6M 7M 6M 4M 4M 4M 3M 3M 764 000
incomeBeforeTax -34M -31M -29M -30M -26M -21M -23M -19M -17M
incomeBeforeTaxRatio 0 0 0 -13.385 0 0 0 0 0
incomeTaxExpense 0 0 481 724 4M -497 000 0 -3M -3M -764 000
netIncome -34M -31M -29M -30M -26M -21M -20M -17M -17M
netIncomeRatio 0 0 0 -13.385 0 0 0 0 0
eps -0.36 -0.34 -0.33 -0.47 -0.41 -0.34 -0.31 -0.31 -0.32
epsdiluted -0.36 -0.34 -0.33 -0.47 -0.41 -0.34 -0.31 -0.31 -0.32
weightedAverageShsOut 94M 94M 88M 65M 63M 63M 63M 54M 52M
weightedAverageShsOutDil 94M 94M 88M 65M 63M 63M 63M 54M 52M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EWTX EWTX EWTX EWTX EWTX EWTX EWTX EWTX EWTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-05-09 2024-02-22 2023-11-09 2023-08-10 2023-05-11 2023-02-23 2022-11-03
acceptedDate 2024-11-07 08:07:49 2024-08-08 08:06:22 2024-05-09 08:06:03 2024-02-22 08:07:05 2023-11-09 08:05:32 2023-08-10 08:01:45 2023-05-11 08:01:07 2023-02-23 16:01:20 2022-11-03 08:00:53
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 45M 43M 30M 86M 33M 32M 48M 22M 110M
shortTermInvestments 448M 468M 502M 232M 257M 278M 280M 330M 255M
cashAndShortTermInvestments 493M 512M 533M 318M 290M 310M 328M 352M 365M
netReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 7M 8M 9M 9M 8M 7M 5M 5M 5M
totalCurrentAssets 499M 519M 541M 327M 298M 317M 328M 357M 370M
propertyPlantEquipmentNet 12M 12M 12M 13M 13M 13M 13M 10M 7M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 262 000 262 000 0 348 000 467 000 419 000 6M 251 000 264 000
totalNonCurrentAssets 12M 12M 12M 13M 13M 14M 18M 10M 7M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 511M 532M 554M 340M 311M 331M 346M 367M 377M
accountPayables 6M 7M 5M 4M 5M 4M 4M 6M 6M
shortTermDebt 992 000 2M 984 000 980 000 931 000 872 000 797 000 608 000 216 000
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 -988 000 0 0 0 0 0 0 0
otherCurrentLiabilities 12M 8M 9M 12M 10M 10M 8M 10M 7M
totalCurrentLiabilities 19M 17M 15M 17M 16M 14M 13M 17M 13M
longTermDebt 3M 4M 4M 4M 5M 5M 5M 4M 2M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 -1 0 -0 0 0 0 -4M
totalNonCurrentLiabilities 3M 4M 4M 4M 5M 5M 5M 4M 2M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 4M 5M 4M 5M 6M 6M 6M 4M 3M
totalLiabilities 22M 21M 19M 21M 21M 19M 18M 20M 16M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 9000 9000 9000 7000 6000 6000 6000 6000 6000
retainedEarnings -339M -305M -273M -245M -215M -189M -167M -145M -125M
accumulatedOtherComprehensiveIncomeLoss 1M -1M -861 000 99 000 -424 000 -547 000 -251 000 -1M -2M
othertotalStockholdersEquity 827M 816M 809M 563M 505M 501M 497M 493M 489M
totalStockholdersEquity 489M 510M 535M 319M 290M 311M 329M 347M 361M
totalEquity 489M 510M 535M 319M 290M 311M 329M 347M 361M
totalLiabilitiesAndStockholdersEquity 511M 532M 554M 340M 311M 331M 346M 367M 377M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 511M 532M 554M 340M 311M 331M 346M 367M 377M
totalInvestments 448M 468M 502M 232M 257M 278M 280M 330M 255M
totalDebt 4M 5M 5M 5M 6M 6M 6M 4M 3M
netDebt -40M -39M -25M -81M -27M -26M -43M -18M -107M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EWTX EWTX EWTX EWTX EWTX EWTX EWTX EWTX EWTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-05-09 2024-02-22 2023-11-09 2023-08-10 2023-05-11 2023-02-23 2022-11-03
acceptedDate 2024-11-07 08:07:49 2024-08-08 08:06:22 2024-05-09 08:06:03 2024-02-22 08:07:05 2023-11-09 08:05:32 2023-08-10 08:01:45 2023-05-11 08:01:07 2023-02-23 16:01:20 2022-11-03 08:00:53
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -34M -31M -29M -30M -26M -21M -23M -19M -17M
depreciationAndAmortization 602 000 534 000 525 000 533 000 497 000 461 000 241 000 92 000 165 000
deferredIncomeTax 0 0 0 -3M 2M 1M 0 0 0
stockBasedCompensation 7M 5M 5M 5M 5M 4M 4M 4M 3M
changeInWorkingCapital -874 000 3M -2M -201 000 974 000 -342 000 -2M 6M 2M
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables -1M 2M 780 000 -1M 2M -312 000 -160 000 576 000 938 000
otherWorkingCapital 154 000 1M -3M 1M -788 000 -30 000 -2M 5M 1M
otherNonCashItems 147 000 846 000 2M -2M -5M -4M -2M -2M 127 000
netCashProvidedByOperatingActivities -27M -26M -29M -27M -22M -20M -23M -12M -12M
investmentsInPropertyPlantAndEquipment -520 000 -221 000 -297 000 -161 000 -457 000 -759 000 -4M -3M -1M
acquisitionsNet 0 0 0 -27 144 -23 876 0 0 0 0
purchasesOfInvestments -45M -41M -328M -40M -85M -114M -17M -147M -68M
salesMaturitiesOfInvestments 71M 79M 60M 67M 109M 119M 70M 74M 43M
otherInvestingActivites 0 38M -268M 27 144 23 876 0 0 0 0
netCashUsedForInvestingActivites 25M 37M -268M 27M 23M 3M 49M -76M -26M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -4M 2M 241M 53M -211 000 0 0 -555 000 130M
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M 2M 2M 53M -211 0 21 000 217 000 5000
netCashUsedProvidedByFinancingActivities 3M 2M 241M 53M -211 000 369 000 21 000 -338 000 130M
effectOfForexChangesOnCash 0 0 0 -24M 3M 20M 0 0 0
netChangeInCash 1M 13M -56M 53M 1M -16M 26M -88M 91M
cashAtEndOfPeriod 45M 43M 30M 86M 33M 32M 48M 22M 110M
cashAtBeginningOfPeriod 43M 30M 86M 33M 32M 48M 22M 110M 18M
operatingCashFlow -27M -26M -29M -27M -22M -20M -23M -12M -12M
capitalExpenditure -520 000 -221 000 -297 000 -161 000 -457 000 -759 000 -4M -3M -1M
freeCashFlow -28M -26M -29M -27M -23M -21M -27M -15M -13M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-07 13:00 ET
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
2024-10-01 12:00 ET
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
2024-09-19 11:00 ET
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
2024-09-17 20:01 ET
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
2024-08-08 12:00 ET
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
2024-05-10 12:00 ET
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
2024-05-09 12:00 ET
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
2024-05-07 12:00 ET
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
2024-05-06 12:00 ET
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
2024-04-23 12:00 ET
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
2024-04-15 20:05 ET
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
2024-03-28 12:00 ET
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
2024-03-27 12:00 ET
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
2024-03-05 13:00 ET
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
2024-02-28 13:00 ET
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
2024-02-22 13:00 ET
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2024-02-13 13:00 ET
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
2024-01-19 13:37 ET
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
2024-01-09 13:39 ET
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 13:00 ET
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
2023-12-18 13:00 ET
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
2023-11-30 13:00 ET
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
2023-11-09 13:00 ET
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
2023-11-08 13:00 ET
Edgewise Therapeutics to Present at Upcoming Investor Conferences
2023-11-01 12:00 ET
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
2023-10-26 12:00 ET
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
2023-09-27 12:00 ET
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
2023-09-26 12:00 ET
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
2023-09-14 12:00 ET
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
2023-08-10 12:00 ET
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2023-06-26 20:01 ET
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
2023-06-06 12:00 ET
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
2023-05-11 12:00 ET
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
2023-05-02 12:00 ET
Edgewise Therapeutics to Present at Upcoming Investor Conferences
2023-03-30 20:01 ET
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
2023-03-21 12:00 ET
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
2023-03-14 12:00 ET
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
2023-03-06 13:00 ET
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
2023-03-01 13:00 ET
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
2023-02-28 13:00 ET
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
2023-02-23 13:00 ET
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
2023-02-07 13:00 ET
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
2023-01-04 13:30 ET
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
2022-12-21 14:00 ET
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
2022-12-20 14:00 ET
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
2022-11-09 13:00 ET
Edgewise Therapeutics to Present at Upcoming Investor Conferences
2022-11-03 12:00 ET
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
2022-10-27 20:05 ET
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
2022-10-13 20:30 ET
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
2022-10-06 12:00 ET
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
2022-09-16 20:05 ET
Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2022-09-14 01:17 ET
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2022-09-13 12:49 ET
Edgewise Therapeutics Announces Proposed Offering of Common Stock
2022-09-11 21:00 ET
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
2022-09-07 12:00 ET
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
2022-08-04 12:00 ET
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
2022-08-03 12:00 ET
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
2022-07-12 12:00 ET
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
2022-06-20 12:00 ET
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
2022-06-16 12:00 ET
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
2022-05-31 12:00 ET
Edgewise Therapeutics to Present at Upcoming Investor Conferences
2022-05-11 12:00 ET
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
2022-05-03 12:00 ET
Edgewise Therapeutics to Present at Upcoming Investor Conferences
2022-04-14 12:00 ET
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
2022-03-08 13:00 ET
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference
2022-02-24 13:00 ET
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-02 14:00 ET
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
2022-01-05 13:00 ET
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
2021-12-15 14:00 ET
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
2021-11-17 14:00 ET
Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2
2021-11-10 13:00 ET
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
2021-10-28 10:00 ET
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients
2021-09-14 13:00 ET
Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
2021-08-16 13:00 ET
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)
2021-08-09 13:00 ET
Edgewise Therapeutics Reports Second Quarter 2021 Financial Results
2021-08-04 13:00 ET
Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11
2021-06-22 13:00 ET
Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference
2021-06-01 13:00 ET
Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-13 20:01 ET
 Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
2021-05-04 13:00 ET
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy
2021-04-27 13:00 ET
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer
2021-03-30 20:01 ET
Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2021-03-26 02:23 ET
Edgewise Therapeutics Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2025-03-03 08:05 ET
Edgewise Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-03 08:00 ET
Edgewise Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-03 08:00 ET
Edgewise Therapeutics, Inc. published news for 2024 q4
SEC form 10
2025-03-03 00:00 ET
Edgewise Therapeutics, Inc. reported for 2024 q4
SEC form 10
2024-11-07 08:07 ET
Edgewise Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-07 08:00 ET
Edgewise Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-07 08:00 ET
Edgewise Therapeutics, Inc. published news for 2024 q3
SEC form 10
2024-08-08 08:06 ET
Edgewise Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-08 08:00 ET
Edgewise Therapeutics, Inc. published news for 2024 q2
SEC form 8
2024-08-08 08:00 ET
Edgewise Therapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Edgewise Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-05-09 00:00 ET
Edgewise Therapeutics, Inc. published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Edgewise Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Edgewise Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-02-22 08:07 ET
Edgewise Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-22 08:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-22 08:00 ET
Edgewise Therapeutics, Inc. published news for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-01-19 00:00 ET
Edgewise Therapeutics, Inc. published news for 2023 q4
SEC form 10
2023-11-09 08:05 ET
Edgewise Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-09 08:00 ET
Edgewise Therapeutics, Inc. published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-10 08:01 ET
Edgewise Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-10 08:00 ET
Edgewise Therapeutics, Inc. published news for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Edgewise Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-14 16:05 ET
Edgewise Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-21 21:57 ET
Edgewise Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-16 16:08 ET
Edgewise Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-09 20:30 ET
Edgewise Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-11 08:01 ET
Edgewise Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-11 08:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Edgewise Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:05 ET
Edgewise Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-03-06 16:21 ET
Edgewise Therapeutics, Inc. published news for 2022 q4
SEC form 10
2023-02-23 16:01 ET
Edgewise Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-02-23 08:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q4
SEC form 6
2022-11-03 08:00 ET
Edgewise Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-03 08:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Edgewise Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-09-14 17:03 ET
Edgewise Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-09-13 08:51 ET
Edgewise Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-04 08:01 ET
Edgewise Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-04 08:00 ET
Edgewise Therapeutics, Inc. published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Edgewise Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-06-24 16:11 ET
Edgewise Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-11 08:01 ET
Edgewise Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-05-11 08:00 ET
Edgewise Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Edgewise Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-11 00:00 ET
Edgewise Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-05-02 16:48 ET
Edgewise Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-02-28 20:04 ET
Edgewise Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-02-24 08:34 ET
Edgewise Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-02-24 08:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-05 08:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q4
SEC form 10
2021-11-10 08:01 ET
Edgewise Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-10 08:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-28 06:02 ET
Edgewise Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-08-09 09:01 ET
Edgewise Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-09 09:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-05-13 16:31 ET
Edgewise Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-05-13 16:02 ET
Edgewise Therapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Edgewise Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-03-30 16:43 ET
Edgewise Therapeutics, Inc. published news for 2020 q4
SEC form 6
2021-03-30 15:42 ET
Edgewise Therapeutics, Inc. published news for 2020 q4
SEC form 6
2021-03-25 18:27 ET
Edgewise Therapeutics, Inc. published news for 2020 q4